Host Defense® Cordyceps (Cordyceps militaris): The Pharmacist's Guide to Energy, Endurance & Immune Support

Dai Tran, PharmD, MBA, B.S.

CEO & Lead Pharmacist, Khang Pharmacy • CA/MN/TX Licensed Pharmacist

Clinical Insights Series • APhA Immunization Certified • 10+ Years Clinical Experience

What Is Host Defense® Cordyceps?

Host Defense® Cordyceps is a single-mushroom dietary supplement providing certified organic Cordyceps militaris mycelium and fermented brown rice biomass. This article covers the capsule form (60 vegetarian capsules). Host Defense also offers Cordyceps in powder and liquid extract forms with different serving sizes and directions; confirm the specific product you are evaluating before comparing doses to clinical studies.

This article reviews the published human evidence for Cordyceps preparations most relevant to this product, applies the Clinical Insights three-tier evidence framework, and is explicit about what has not been established for the Host Defense® Cordyceps finished product.

Supplement Facts (Per 2-Capsule Serving)

Serving size: 2 vegetarian capsules | Servings per container: 30 | Suggested use: Take 2 capsules once per day, with food or on an empty stomach, or as recommended by your healthcare professional

Other ingredients: Pullulan (capsule). Gluten-free. Non-GMO Project Verified. Certified Organic. Vegan.

Cordyceps militaris vs. Cordyceps sinensis: Key Differences

Two primary species of Cordyceps are used in supplementation. Cordyceps sinensis is the species historically used in Traditional Chinese Medicine, harvested from the Tibetan Plateau. Cordyceps militaris has attracted increasing scientific interest because it can be cultivated under controlled conditions. Cordycepin (3’-deoxyadenosine), an adenosine analog found in Cordyceps species, is present at measurable concentrations in C. militaris. Comparative concentration data between wild C. sinensis and cultivated C. militaris varies substantially by source, preparation method, and analytical method; specific fold-difference claims should be interpreted with that variability in mind.

What the Evidence Does — and Does Not — Establish

• Exercise performance (human RCT evidence, C. sinensis): A 12-week RCT of Cs-4 (C. sinensis fermentation extract) found a significant improvement in ventilatory threshold but not VO2 max in healthy older adults. This preparation differs in species and formulation from Host Defense® Cordyceps.
• Exercise performance (human RCT evidence, mushroom blend including C. militaris): A 3-week RCT using a multi-mushroom blend containing C. militaris found favorable trends in VO2 max and some exercise measures after 3 weeks; acute effects were not significant. The intervention was a multi-ingredient blend, not a single-species product equivalent to Host Defense® Cordyceps Capsules.
• Immune modulation (preliminary human biomarker evidence): Human randomized evidence demonstrates preliminary effects on immune biomarkers such as NK-cell activity, but the studies used different C. militaris preparations and do not establish clinically meaningful outcomes such as reduced infection risk or efficacy of Host Defense® Cordyceps Capsules.
• Not established: That Host Defense® Cordyceps Capsules at 1,000 mg/day produce specific exercise, energy, or immune outcomes in a published, independently conducted RCT of the current formulation and dose.

Ingredient Evidence Review

1. Energy & Athletic Performance

• HUMAN RCT (C. sinensis Cs-4): Chen S et al. (PMID: 20804368) evaluated Cs-4, a standardized Cordyceps sinensis fermentation product, at 333 mg three times daily (~1,000 mg/day) for 12 weeks in healthy older adults in a double-blind, placebo-controlled trial. Ventilatory threshold increased significantly versus placebo; VO2 max did not significantly change. Because Cs-4 is a C. sinensis fermentation extract — differing in species, preparation, and formulation from Host Defense® Cordyceps Capsules — these results should not be treated as direct evidence for the finished product.
• HUMAN RCT — MIXED (mushroom blend including C. militaris): Hirsch KR et al. (PMID: 27408987) evaluated a commercially available multi-mushroom blend containing C. militaris at 4,000 mg/day in healthy young adults. Acute supplementation did not significantly improve exercise-performance measures. After 3 weeks, some measures including VO2 max showed favorable trends, with additional exercise outcomes also trending positively. Because the intervention was a multi-ingredient mushroom preparation — not the Host Defense® Cordyceps single-species capsule product — and was used at four times the Host Defense® capsule dose, these findings cannot establish efficacy for Host Defense® Cordyceps Capsules.
• HUMAN RCT — NULL RESULT (Cs-4): Parcell AC et al. (PMID: 15118196) evaluated CordyMax Cs-4 at 3,000 mg/day for five weeks in 22 endurance-trained male cyclists. The trial did not improve VO2peak, ventilatory threshold, or endurance time-trial performance. This negative result further supports a mixed interpretation of the exercise literature and involved a different C. sinensis preparation, dose, and population from Host Defense® Cordyceps Capsules.
• REVIEW — HUMAN EXERCISE EVIDENCE: Jędrejko M et al. (PMID: 41829950) identified five human C. militaris intervention studies published from 2017–2024, involving 321 participants. Preparations, doses, durations, and study designs varied substantially, limiting direct comparison and product-specific inference. The review supports continued investigation of C. militaris for exercise and recovery but does not establish efficacy of Host Defense® Cordyceps Capsules.
• PRECLINICAL: Animal and in-vitro studies have evaluated Cordyceps preparations for effects on ATP synthesis and mitochondrial function. These findings reflect preclinical mechanisms and cannot be directly extrapolated to human clinical outcomes at supplement doses.
• What this does not establish: That Host Defense® Cordyceps Capsules at 1,000 mg/day produces VO2 max improvements, significant fatigue reduction, or specific athletic performance benefits equivalent to outcomes seen in any of the cited trials.

2. Cordycepin and Adenosine Biology

Cordycepin (3’-deoxyadenosine) is structurally similar to adenosine and has been studied preclinically for effects on mTOR signaling, NF-κB inhibition, and inflammatory cytokine regulation. Most of this evidence is in vitro or from animal models. Oral bioavailability of cordycepin is subject to rapid deamination by adenosine deaminase, which may limit systemic exposure at supplement doses. Robust human clinical trials evaluating cordycepin-specific outcomes at supplement doses are limited.

• PRECLINICAL / MECHANISTIC: NF-κB inhibition, mTOR pathway effects, and cytokine modulation have been demonstrated in cell and animal models. These are mechanistic signals, not established human clinical outcomes.
• What this does not establish: That cordycepin at supplement doses produces anti-inflammatory, longevity, or other clinical effects in humans.

3. Immune Modulation

Cordyceps species contain beta-glucans and polysaccharides that have shown immune-modulatory activity in preclinical models and some early clinical studies, including effects on NK cell activity and macrophage activation.

• HUMAN RCT — IMMUNE BIOMARKERS / DIFFERENT C. militaris PREPARATION: Kang HJ et al. (PMID: 26284906) evaluated 1,500 mg/day of an ethanol-treated C. militaris preparation for four weeks in healthy Korean men. The study reported increases in NK-cell activity, lymphocyte proliferation, and selected Th1-associated cytokine measures compared with placebo. This was a different concentrated preparation from Host Defense® Cordyceps mycelium/fermented brown-rice biomass and did not establish finished-product efficacy.
• HUMAN RCT — IMMUNE BIOMARKERS: Ontawong A et al. (PMID: 38580687) evaluated a fermented C. militaris beverage for eight weeks in healthy adults. Some changes in NK-cell activity and selected inflammatory or immune markers were observed, while routine safety indices did not differ between groups. The study used a different fermented preparation and did not establish reduced infection risk, clinically meaningful immune outcomes, or efficacy of Host Defense® Cordyceps Capsules.
• PRECLINICAL / MECHANISTIC: Animal models and in-vitro systems provide additional signals involving immune-cell activity and inflammatory pathways, but these findings do not establish clinical benefit in humans.
• What this does not establish: That Host Defense® Cordyceps Capsules produces measurable immune-function improvements in healthy adults, or that NK-cell activity changes in laboratory assays translate to clinically relevant outcomes.

4. Host Defense® Cultivation and Formulation

Host Defense® Cordyceps Capsules contain Cordyceps militaris mycelium cultivated on certified organic brown rice, with the fermented substrate retained in the finished product. This cultivation approach produces a composition that differs materially from standardized Cs-4 fermentation extracts and other concentrated Cordyceps preparations used in published clinical trials. Host Defense does not isolate or concentrate specific compounds such as cordycepin; its quality testing focuses on identity, composition, purity, and strength. Claims about specific bioactive concentrations in the finished product should not be assumed without product-specific analytical data.

Important Safety Considerations

• Immunosuppressive medications (cyclosporine, tacrolimus, corticosteroids): Cordyceps preparations have immune-modulatory activity. Discuss with your pharmacist or physician before use if you are on immunosuppressive therapy.
• Anticoagulants and antiplatelet agents (warfarin, aspirin, clopidogrel): Some Cordyceps preparations have shown mild antiplatelet activity in preclinical studies; discuss with your pharmacist before use.
• Autoimmune conditions: Immune-modulating supplements should be used with physician oversight in patients with autoimmune disease.
• Pregnancy and lactation: Insufficient human safety data; Host Defense advises consulting a healthcare professional before use. Avoid unless directed by a physician.

Who May Consider Discussing Host Defense® Cordyceps?

• Active adults interested in discussing adaptogenic mushroom support for endurance and recovery under pharmacist or physician guidance
• Healthy adults interested in discussing non-stimulant mushroom supplementation as part of a broader wellness plan
• Individuals interested in immune-supportive mushroom supplementation
• Not appropriate without pharmacist or physician review: Patients on immunosuppressive medications, anticoagulants, or with active autoimmune conditions.

Pharmacist’s Note

As a PharmD, I discuss Host Defense® Cordyceps Capsules with patients interested in adaptogenic mushroom support for energy, endurance, or immune function. I am transparent that the best-available human RCT evidence uses Cordyceps sinensis Cs-4 fermentation extract or a multi-mushroom blend containing C. militaris. Although the Cs-4 trial used a nominal daily amount of approximately 1,000 mg/day — similar to the labeled daily amount of Host Defense® Cordyceps Capsules — the species and preparation differ materially. The C. militaris-containing exercise trial used a multi-ingredient preparation at 4,000 mg/day. No published finished-product RCT exists for this specific product. I discuss the certified organic mycelium-on-substrate cultivation approach as a distinguishing feature while being clear that it does not constitute independently validated evidence of efficacy. I screen for immunosuppressive medications and anticoagulants before recommending. Free PharmD consultation: (408) 622-8068.

Selected Key Studies

1. HUMAN RCT Chen S, Li Z, Krochmal R, Abrazado M, Kim W, Cooper CB. Effect of Cs-4 (Cordyceps sinensis) on exercise performance in healthy older subjects: a double-blind, placebo-controlled trial. J Altern Complement Med. 2010;16(5):585–590. doi: 10.1089/acm.2009.0226. PMID: 20804368.
   Double-blind, placebo-controlled trial; Cs-4 (C. sinensis fermentation preparation) 333 mg three times daily (~1,000 mg/day) for 12 weeks in healthy older adults. Ventilatory threshold improved significantly versus placebo; VO2 max did not significantly change. Formulation, species, and preparation all differ from Host Defense® Cordyceps Capsules.
2. HUMAN RCT — MIXED Hirsch KR, Smith-Ryan AE, Roelofs EJ, Trexler ET, Mock MG. Cordyceps militaris Improves Tolerance to High-Intensity Exercise After Acute and Chronic Supplementation. J Diet Suppl. 2017;14(1):42–53. doi: 10.1080/19390211.2016.1203386. PMID: 27408987.
   Randomized, double-blind, placebo-controlled trial; multi-mushroom blend containing C. militaris at 4,000 mg/day in healthy young adults. Acute effects were not significant. After 3 weeks, VO2 max and some exercise measures showed favorable trends. This was not the Host Defense® Cordyceps capsule product.
3. HUMAN RCT — NULL RESULT Parcell AC, Smith JM, Schulthies SS, Myrer JW, Fellingham G. Cordyceps Sinensis (CordyMax Cs-4) supplementation does not improve endurance exercise performance. Int J Sport Nutr Exerc Metab. 2004;14(2):236–242. doi: 10.1123/ijsnem.14.2.236. PMID: 15118196.
   Randomized placebo-controlled trial in 22 endurance-trained male cyclists; CordyMax Cs-4 3,000 mg/day for five weeks. VO2peak, ventilatory threshold, and endurance time-trial performance did not improve.
4. REVIEW Jędrejko M, Jędrejko K, Granda D, Kała K, Pokrywka A, Muszyńska B. Current Evidence of Ergogenic and Post-Exercise Recovery Effects of Dietary Supplementation with Cordyceps militaris in Humans—A Narrative Review. Nutrients. 2026;18(5):781. doi: 10.3390/nu18050781. PMID: 41829950.
   Identified five human C. militaris intervention studies from 2017–2024 involving 321 participants. Preparations, doses, durations, and study designs varied substantially, limiting direct comparison and product-specific inference.
5. HUMAN RCT — IMMUNE BIOMARKERS Kang HJ, Baik HW, Kim SJ, Lee SG, Ahn HY, Park JS, Park SJ, Jang EJ, Park SW, Choi JY, Sung JH, Lee SM. Cordyceps militaris Enhances Cell-Mediated Immunity in Healthy Korean Men. J Med Food. 2015;18(10):1164–1172. doi: 10.1089/jmf.2014.3350. PMID: 26284906.
   Healthy Korean men received 1,500 mg/day of an ethanol-treated C. militaris preparation for four weeks. NK-cell activity, lymphocyte proliferation, and selected Th1-associated cytokine measures increased versus placebo; the preparation differed from Host Defense® Cordyceps Capsules.
6. HUMAN RCT — IMMUNE BIOMARKERS Ontawong A, Pengnet S, Thim-Uam A, Munkong N, Narkprasom N, Narkprasom K, Kuntakhut K, Kamkeaw N, Amornlerdpison D. A randomized controlled clinical trial examining the effects of Cordyceps militaris beverage on the immune response in healthy adults. Sci Rep. 2024;14(1):7994. doi: 10.1038/s41598-024-58742-z. PMID: 38580687.
   A 2024 randomized trial evaluated a fermented C. militaris beverage for eight weeks in healthy adults. Some NK-cell and inflammatory-marker changes were observed, but the study did not establish reduced infection risk, clinically meaningful immune outcomes, or efficacy of Host Defense® Cordyceps Capsules.

Reviewed by: Dai Tran, PharmD, MBA, B.S.  View full bio →

CEO & Lead Pharmacist, Khang Pharmacy • CA/MN/TX Licensed Pharmacist

Clinical Insights Series • APhA Immunization Certified • 10+ Years Clinical Experience

Khang Pharmacy | 2451 S King Rd., Ste A1, San Jose, CA 95122 | (408) 622-8068 | www.khangpharmacy.com